Atypical Epithelial Proliferation in Fallopian Tubes in Prophylactic Salpingo-oophorectomy Specimens from BRCA1 and BRCA2 Germline Mutation Carriers

International Journal of Gynecological Pathology

Volumn 23, Issue 1, 2004, Pages 35-40

  Carcangiu, Maria L ^a,d   Radice, Paolo ^a,c   Manoukian, Siranoush ^a   Spatti, Gianbattista ^b   Gobbo, Morena ^a   Pensotti, Valeria ^a,c   Crucianelli, Rosella ^a,c   Pasini, Barbara ^a  

^a Department of Pathology ^*  (Italy)

^b Ist Naz Stud e la Cura dei Tumori   (Italy)

^c FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Atypical hyperplasia; BRCA1; Carcinoma in situ; Fallopian tube; Prophylactic salpingo oophorectomy

Indexed keywords

ADULT; ARTICLE; CARCINOMA IN SITU; CELL PROLIFERATION; CLINICAL ARTICLE; FEMALE; HETEROZYGOTE; HUMAN; HUMAN TISSUE; HYSTERECTOMY; PRIORITY JOURNAL; PROPHYLAXIS; SALPINGOOOPHORECTOMY; UTERINE TUBE; UTERINE TUBE CARCINOMA; UTERUS MYOMA;

CELL DIVISION; EPITHELIAL CELLS; FALLOPIAN TUBE NEOPLASMS; FALLOPIAN TUBES; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; MUTATION; OVARIECTOMY; PRECANCEROUS CONDITIONS;

EID: 0346251021     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pgp.0000101082.35393.84     Document Type: Article

References (35)

1. Baekelandt M, Kock M, Wesling F, et al. Primary adenocarcinoma of the fallopian tube. Review of the literature. Int J Gynecol Cancer 1993;3:65-71.
2. Rosenblatt KA, Weiss NS, Schwartz SM. Incidence of malignant fallopian tube tumors. Gynecol Oncol 1989;35:236-9.
3. Vinall PS, Buxton N, Cowen PN. Primary carcinoma of the fallopian tube associated with tuberculous salpingitis: a case report. Br J Obstet Gynaecol 1979;86:984-9.
4. Agoff SN, Mendelin JE, Grieco VS, et al. Unexpected gynecologic neoplasms in patients with proven or suspected BRCA-1 or -2 mutations: implications for gross examination, cytology, and clinical follow-up. Am J Surg Pathol 2002;26:171-8.
5. Aziz S, Kuperstein G, Rosen B, et al. A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol 2001;80:341-5.
6. Colgan TJ, Murphy J, Cole DE, et al. Occult carcinoma in prophylactic oophorectomy specimens. Prevalence and association with BRCA germline mutation status. Am J Surg Pathol 2001;25:1283-9.
7. Hartley A, Rollason T, Spooner D. Clear cell carcinoma of the fimbria of the fallopian tube in a BRCA1 carrier undergoing prophylactic surgery. Clin Oncol 2000;12:58-9.
8. Paley PJ, Swisher EM, Garcia RL, et al. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. Gynecol Oncol 2001;80:176-80.
9. Piek JM, van Diest PJ, Zweemer RP, et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2000;195:451-6.
10. Rose PG, Shrigley R. Wiesner GL. Germline BRCA2 mutation in a patient with fallopian tube carcinoma: a case report. Gynecol Oncol 2000;77:319-20.
11. Schubert EL, Lee MK, Mefford HC, et al. BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2. Am J Hum Genet 1997;60:1031-40.
12. Tong D, Stimpfl M, Reinthaller A, et al. BRCA1 gene mutations in sporadic ovarian carcinomas: detection by PCR and reverse allele-specific oligonucleotide hybridization. Clin Chem 1999;45:976-81.
13. Tonin P, Moslehi R, Green et al. Linkage analysis of 26 Canadian breast and breast-ovarian cancer families. Hum Genet 1995;95:545-50.
14. Zweemer RP, van Diest PJ, Verheijen RHM, et al. Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol Oncol 2000;76:45-50.
15. De Benedetti VM, Radice P, Pasini B, et al. Characterization of ten novel and 13 recurring BRCA1 and BRCA2 germline mutations in Italian breast and/or ovarian carcinoma patients. Mutations in brief no.178. Online. Hum Mutat 1998;12:215.
16. Carcangiu ML, Radice P, Spatti G, et al. Incidental tumors in prophylactic oophorectomy specimens from BRCA mutation carriers. Modern Pathol 2003;16:184A.
17. Yanai-Inbar I, Siriaunkgul S, Silverberg SG. Mucosal epithelial proliferation of the fallopian tube: a particular association with ovarian serous tumor of low malignant potential? Int J Gynecol Pathol 1995;14:107-13.
18. Scully RE, Young RH, Clement PB. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. In: Atlas of Tumor Pathology. Third series. Fascicle 23. Washington, DC: Armed Forces Institute of Pathology; 1998.
19. Thompson D, Easton D. Breast Cancer Linkage Consortium. Variation in cancer risk, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 2001;68:410-9.
20. Salazar H, Godwin AK, Daly MB, et al. Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst 1996;88:1810-20.
21. Barakat RR, Federici MG, Saigo PE, et al. Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes. Cancer 2000;89:383-90.
22. Clement PB, Young RH. Atlas of Gynecologyc Surgical Pathology. Philadelphia: WB Saunders; 2000.
23. Stern J, Buscema J, Parmley T, et al. Atypical epithelial proliferations in the fallopian tube. Am J Obstet Gynecol 1981;140:309-12.
24. Moore SW, Enterline HT. Significance of proliferative epithelial lesions of the uterine tube. Obstet Gynecol 1975;45:385-90.
25. Robey SS, Silva EG. Epithelial hyperplasia of the fallopian tube. Its association with serous borderline tumors of the ovary. Int J Gynecol Pathol 1989;8:214-20.
26. Yanai-Inbar I, Silverberg SG. Mucosal epithelial proliferation of the fallopian tube: prevalence, clinical associations, and optimal strategy for histopathologic assessment. Int J Gynecol Pathol 2000;19:139-44.
27. Cheung NY, Young RH, Scully RE. Pseudocarcinomatous hyperplasia of the fallopian tube associated with salpingitis. A report of 14 cases. Am J Surg Pathol 1994;18:1125-30.
28. Sonnendecker HE, Cooper K, Kalian KN. Primary fallopian tube adenocarcinoma in situ associated with adjuvant therapy for breast carcinoma. Gynecol Oncol 1994;52:402-7.
29. Pickel H, Reich O, Tamussino K. Bilateral atypical hyperplasia of the fallopian tube associated with Tamoxifen: a report of two cases. Int J Gynecol Pathol 1998;17:284-5.
30. Chung TK, Cheung TH, To KF, et al. Overexpression of p53 and HER-2/neu and c- myc in primary fallopian tube carcinoma. Gynecol Obstet Invest 2000;49:47-51.
31. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazy Jews. N Engl J Med 1997;336:1401-8.
32. Piver MS, Jishi MF, Tsukada Y, et al. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 1993;71:2751-5.
33. Narod SA, Brunet JS, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 2000;356:1876-81.
34. Jordan VC, Assikis VJ. Endometrial carcinoma and tamoxifen: clearing up a controversy. Clin Cancer Res 1995;1:467-72.
35. Diwan BA, Anderson LM, Ward JM. Proliferative lesions of oviduct and uterus in CD-1 mice exposed prenatally to tamoxifen. Carcinogenesis 1977;18:2009-14.